Sun Pharma said the pancreatitis drug, nafamostat mesilate, has been identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany BENGALURU : Drugmaker Sun Pharmaceutical Industries Ltd said on Friday it has received Indian regulatory approval to start clinical trials of a pancreatitis drug in COVID-19 patients.
The company joins other Indian drugmakers Glenmark Pharmaceuticals Ltd and Strides Pharma Science Ltd that are conducting trials in India for potential drugs for COVID-19, which currently has no approved treatment or vaccine.